Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 19/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720418 | 0.80 | NOTUM (0.60) | NOTUMCYP1A2KDM4EALDH1A1GLA | |
| SCHEMBL5757848 | 0.78 | NOTUM (1.00) | NOTUMCYP1A2 | |
| SCHEMBL31028720 | 0.77 | NOTUM (0.74) | NOTUMCYP1A2 | |
| SCHEMBL14531216 | 0.76 | KMO (0.52) | — | |
| SCHEMBL18394490 | 0.76 | NOTUM (0.72) | NOTUM | |
| SCHEMBL182023 | 0.75 | NOTUM (1.00) | NOTUM | |
| SCHEMBL2123523 | 0.74 | S1PR1 (0.57) | NOTUM | |
| SCHEMBL12896228 | 0.73 | NOTUM (0.66) | NOTUMKDM4EALDH1A1GLAHSD17B10 | |
| SCHEMBL2124854 | 0.73 | S1PR1 (0.50) | — | |
| SCHEMBL2126187 | 0.73 | S1PR1 (0.50) | NOTUMKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1951719-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NOTUM 3426/4885CYP1A2 4665/4885KDM4E 3267/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NOTUM 3426/4885CYP1A2 4665/4885KDM4E 3267/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | NOTUM 3426/4885CYP1A2 4665/4885KDM4E 3267/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | NOTUM 3264/4885CYP1A2 4636/4885KDM4E 3116/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NOTUM 3426/4885CYP1A2 4665/4885KDM4E 3267/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NOTUM 3426/4885CYP1A2 4665/4885KDM4E 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.